分组1 - Septerna, Inc. reported a quarterly loss of $0.24 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.23, but an improvement from a loss of $0.64 per share a year ago, indicating an earnings surprise of -5.50% [1] - The company posted revenues of $24.12 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 17.98%, compared to revenues of $0.21 million in the same quarter last year [2] - Over the last four quarters, Septerna has not surpassed consensus EPS estimates, achieving this only once for revenue estimates [2] 分组2 - The stock has increased by approximately 3.2% since the beginning of the year, contrasting with a 1.5% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $20.86 million, and for the current fiscal year, it is -$1.11 on revenues of $82.26 million [7] - The Medical - Biomedical and Genetics industry, to which Septerna belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates